| Business Summary | | Atlantic
Technology
Ventures,
Inc.
is
engaged
in
the
business
of
developing
and
commercializing
early
stage
technologies.
The
Company
has
been
focused
on
biomedical
and
pharmaceutical
technologies,
and
is
developing
two
such
technologies
that
may
be
useful
in
treating
a
variety
of
diseases,
including
cancer,
infectious
disease,
pain
and
inflammation.
The
Company
is
also
entitled
to
royalties
and
other
revenues
in
connection
with
commercialization
of
technology
relating
to
cataract
surgery.
Atlantic
Technology
has
also
expanded
its
focus,
and
seeks
to
develop
and
commercialize
a
diverse
portfolio
of
patented
technologies.
The
Company's
acquisition
of
an
ownership
interest
in
a
company
that
is
developing
high-speed
fiber-optic
communication
technologies
represents
its
first
investment
in
an
electronic
infrastructure
technology. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Atlantic
Technology
Ventures
is
engaged
in
developing
and
commercializing
a
diverse
portfolio
of
patented
technologies.
For
the
three
months
ended
3/31/01,
revenues
totaled
$2.7
million,
up
from
$925
thousand.
Net
income
applicable
to
Common
totaled
$856
thousand,
vs.
a
loss
of
$2
million.
Revenues
reflect
the
recognition
of
a
project
completion
bonus
in
February.
Net
income
also
reflects
a
gain
on
sale
of
Optex
assets,
higher
operating
margins
and
lower
compensation
expense. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY2000 Pay | |
| Frederic Zotos, 35 Pres,
CEO, Director | $206K | Nicholas Rossettos, 35 CFO | 126K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|